Allergan Gets FDA OK of Juvederm Volume XC for Chin Region

AbbVie Inc.’s Allergan Aesthetics unit on Monday said the U.S. Food and Drug Administration approved its Juvederm Voluma XC filler for the augmentation of the chin region in adults over the age of 21.
Allergan said Juvederm Voluma XC is the first and only filler to receive FDA approval to improve the chin profile.
The clearance marks the second indication for the product, which the agency previously approved in 2013 for cheek augmentation to correct age-related mid-face volume deficit, and the fifth U.S. approved indication for Allergan’s Juvederm collection of fillers.
AbbVie completed its roughly $63 billion acquisition of Allergan in early May.

https://www.marketscreener.com/ABBVIE-INC-12136589/news/AbbVie-Allergan-Gets-FDA-OK-of-Juvederm-Volume-XC-for-Chin-Region-30773497/